However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

MoonLake's shares rose 19% in extended trading. Merck submitted a nonbinding offer for MoonLake earlier this year, according ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

The company’s flagship product, Keytruda, has been a significant driver of growth and revenue in recent years. In the fourth quarter of 2024, Merck surpassed expectations, reporting a 1% beat on ...

(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus c ...

Trodelvy and Keytruda combination shows promise in treating advanced triple-negative breast cancer, improving ...